NGM Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:NGM Biopharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014051
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NGM Biopharmaceuticals Inc (NGM Bio) is a clinical stage biopharmaceutical company which focuses on the development of drug discovery platform to generate biologic drug candidates to treat cardio-metabolic, immuno-oncology and liver diseases. Its product pipeline includes NGM282, NGM386, NGM395, NGM313, NGM217 and NGM120. The company’s drug candidates are being developed for the treatment of various therapeutic indications such as obesity, diabetes, oncology and other indications. NGM Bio developed a biologics platform that incorporates multiple technologies to generate and screen monoclonal antibodies. The company works in collaboration with Merck to discover, develop and commercialize new biologic drugs. NGM Bio is headquartered in South San Francisco, California, the US.

NGM Biopharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
NGM Biopharma Raises USD106 Million in Series E Financing 11
NGM Biopharmaceuticals Secures $36.8 Million Series D Financing 12
NGM Biopharma Raises USD20.7 Million in Series D Financing 13
NGM Biopharma Raises US$50 Million In Series C Venture Financing 14
NGM BioPharma Raises US$16.9 Million In Fourth Tranche Of Series B Financing 15
Partnerships 16
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 16
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 17
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 18
Licensing Agreements 19
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 19
Equity Offering 20
NGM Biopharma Plans IPO 20
NGM Biopharmaceuticals Inc – Key Competitors 21
NGM Biopharmaceuticals Inc – Key Employees 22
NGM Biopharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NGM Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NGM Biopharma Raises USD106 Million in Series E Financing 11
NGM Biopharmaceuticals Secures $36.8 Million Series D Financing 12
NGM Biopharma Raises USD20.7 Million in Series D Financing 13
NGM Biopharma Raises US$50 Million In Series C Venture Financing 14
NGM BioPharma Raises US$16.9 Million In Fourth Tranche Of Series B Financing 15
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 16
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 17
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 18
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 19
NGM Biopharma Plans IPO 20
NGM Biopharmaceuticals Inc, Key Competitors 21
NGM Biopharmaceuticals Inc, Key Employees 22

★海外企業調査レポート[NGM Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CSE Global Ltd (544):石油・ガス:M&Aディール及び事業提携情報
    Summary CSE Global Limited (CSE) is a technology company offering process control systems and integrated plant communication systems. It’s process control systems offers emergency shutdown systems, process shutdown systems, integrated control & safety systems and fire and gas detection systems, well …
  • IP Group Plc (IPO):企業の財務・戦略的SWOT分析
    Summary IP Group Plc (IP Group) is a provider of venture capital, business building and support, networks and recruitment services. The company invests in companies, which comprise early stage to mature businesses from various sectors such as energy and renewables, medical equipment and supplies, ph …
  • Laureate Education, Inc.:企業のM&A・事業提携・投資動向
    Laureate Education, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Laureate Education, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • AstraZeneca PLC:企業の戦略・SWOT・財務情報
    AstraZeneca PLC - Strategy, SWOT and Corporate Finance Report Summary AstraZeneca PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Symphony Ltd:企業の戦略・SWOT・財務分析
    Symphony Ltd - Strategy, SWOT and Corporate Finance Report Summary Symphony Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Voltalia SA (VLTSA):企業の財務・戦略的SWOT分析
    Voltalia SA (VLTSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Christus Health:企業の戦略的SWOT分析
    Christus Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Saudi Industrial Export Company (4140):企業の財務・戦略的SWOT分析
    Summary Saudi Industrial Export Company (SIEC) is a chemical providing company that imports, exports and selss specialty chemicals, fertilizers, industrial materials and commodities. The company's fertilizers include diammonium phosphate, sulphur, urea, triple super phosphate, granular triple super …
  • The Hain Celestial Group Inc (HAIN):企業の財務・戦略的SWOT分析
    The Hain Celestial Group Inc (HAIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Visser & Smit Hanab BV:企業の戦略的SWOT分析
    Visser & Smit Hanab BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Cellmid Ltd (CDY):医療機器:M&Aディール及び事業提携情報
    Summary Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd, is a life sciences company that develops and commercializes diagnostic and therapeutic products. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such a …
  • Horizon Oil Ltd (HZN):石油・ガス:M&Aディール及び事業提携情報
    Summary Horizon Oil Ltd (Horizon) is an oil and gas exploration and production company that acquires, explores, develops and produces oil and petroleum properties. The company holds interests in Maari and Manaia fields located in the Taranaki Basin approximately 80 kilometre offshore the north islan …
  • Aushon BioSystems Inc-医療機器分野:企業M&A・提携分析
    Summary Aushon BioSystems Inc (Aushon) is a medical device provider that offers biomarker measurement and analysis products. The company provides biomarker therapeutic areas in microarray printing technology. Its products include ciraplex assay, cirascan imaging and cirasoft analysis and cira servic …
  • Chronix Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Chronix Biomedical Inc (Chronix Biomedical) is a molecular diagnostic company that develops blood tests for monitoring minimal residual disease in cancer patients. The company offers tests such as second opinion tests and delta dot tests. Its second opinion tests include supplementary blood …
  • GW Pharmaceuticals Plc (GWPH):医療機器:M&Aディール及び事業提携情報
    Summary GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the …
  • Comrod Communication ASA:企業の戦略・SWOT・財務情報
    Comrod Communication ASA - Strategy, SWOT and Corporate Finance Report Summary Comrod Communication ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • KCC Corp (002380):企業の財務・戦略的SWOT分析
    KCC Corp (002380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Sernova Corp (SVA):製品パイプライン分析
    Summary Sernova Corp (Sernova) is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company is developing Cell Pouch System, an implantable medical device, which offers a natural organ- …
  • InterGen Services, Inc.:電力:M&Aディール及び事業提携情報
    Summary InterGen Services, Inc. (InterGen) is an energy utility that develops, owns, and operates power generation assets which produce energy from coal, gas and renewable sources. It is jointly owned by Ontario Teachers’ Pension Plan and China Huaneng Group/Yudean Guandong Group. The company also o …
  • Envases Del Plata S.A.
    Envases Del Plata S.A. - Strategy, SWOT and Corporate Finance Report Summary Envases Del Plata S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆